Cervical Cancer
Conditions
Interventions
single arm:Nab-paclitaxel plus cisplatin weekly radical concurrent radiochemotherapy regimen
Sponsors
The Affiliated People's Hospital of Inner Mongolia Medical University (Inner Mongolia Cancer Hospital)
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with invasive squamous cell carcinoma of the cervix confirmed by biopsy; 2. Patients with pelvic CT, MRI or PET / CT within 1-2 weeks before treatment; 3. Patients with stage ib-iii (FIGO 2018 stage) were determined based on gynecological examination and imaging examination; 4. Patients with general condition score of 0-1; 5. Laboratory examination indexes, including liver function, renal function and bone marrow examination, met the following indexes: (1) White blood cell (WBC): >= 3.5 * 10^9 / L (2) Neutrophil count (ANC): >= 1.5 * 10^9 / L (3) Platelet (PLT): >= 100 * 10^9 / L (4) Total bilirubin (TB): = 50ml / min 6. Patients must sign the informed consent before entering the group.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of malignant tumor or accompanied by a second primary tumor in recent 3 years; 2. Patients with previous history of systemic chemotherapy or pelvic / abdominal radiotherapy; 3. In patients without tumor related surgery, lymph node graft was excluded; 4. Patients with severe infection, heart, liver or kidney disease; 5. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Safety and Tolerability; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall treatment time;quality of life; | — |
Countries
China
Contacts
Public ContactHao Yang
People's Hospital Affiliated to Inner Mongolia Medical University (Cancer Hospital of Inner Mongolia Autonomous Region)
Outcome results
None listed